Imaging features of triple-negative breast cancers according to androgen receptor status.

ABSTRACT:

Objective

Different molecular subtypes of triple-negative breast cancer (TNBC) have previously been identified through analysis of gene expression profiles. The luminal androgen receptor (LAR) subtype has been shown to have a lower rate of pathologic complete response to neoadjuvant chemotherapy than other TNBC subtypes. The purpose of this study was to determine if the imaging features of TNBCs differ by AR (androgen receptor) status, which is a surrogate immunohistochemical (IHC) marker for the chemoresistant LAR subtype of TNBC.

Materials and methods

This sub-study was part of a clinical trial in patients with stage I-III TNBC who were prospectively monitored for response while receiving neoadjuvant systemic therapy (NAST) at a single comprehensive cancer center. This int

SUBMITTER: Candelaria RP 

PROVIDER: S-EPMC6481318 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature